Shine-On BioMedical was listed by Taiwan's emerging market stock exchange with a reference price of $43. SOB101 is the first nucleic acid drug in Taiwan to be developed as an exosome-loaded nucleic acid and chemotherapy drug, and is expected to lead Taiwan's biomedical industry to take its place in the global nucleic acid industry. Shine-On BioMedical has two technology platforms for the development of tri-specific antibodies and one for exosome-loaded nucleic acids, and currently has five drugs in development that have entered the CDMO process and are expected to enter clinical trials in 2023. According to the company, SOA101 tri-specific T-cell conjugate antibodies have been shown in animal studies to have better efficacy than commercially available immune checkpoint monoclonal antibodies, with better inhibition of cancer cell growth and longer survival times in experimental animals.

Another core antibody product, SOA201, is a triple specific conjugated dual immune cell antibody, which uses EphA10 as a tumour target and is designed to bind only to tumour cells, without affecting normal cells. Due to the continuous improvement of antibodies technology, multi-specific antibodies have gradually become the highlight of new antibodies development, but so far no successful tri-specific antibodies have been marketed worldwide, and the commercial value of the future development by Shine-On BioMedical is expected, both in terms of licensing and after the drug is marketed.

In addition, SOB101 is the first exosomal drug to be used in cancer therapy in Taiwan. The nucleic acid drug can inhibit the remote metastasis and invasion of the tumour, while the chemotherapeutic drug can directly kill the tumour cells. This mechanism of drug action can prevent the metastasis of tumour cells after chemotherapy, thus enabling more effective removal of tumour cells. In addition, the carrier platform can also be used to load various antibiotics, which is expected to solve the dilemma of "super-resistant bacteria" without antibiotics, and has great potential for development. Although it is still at the pre-clinical stage, its data from pre-clinical animal studies are so promising that it has already won the attention and recognition of major international pharmaceutical companies, who are seeking to collaborate on its development.